Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316940 · ClinicalTrials.gov registry record · Phase 1
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Oncotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT00316940 is a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Oncotherapeutics. The registered enrollment target is 36 participants, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00316940, a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Oncotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to radiation. Giving samarium 153 together with bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG bortezomib
- RADIATION samarium Sm 153 lexidronam pentasodium
Study Locations (4)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- Hematology-Oncology Medical Group of Fresno, Incorporated - Fresno
- - West Hollywood
Maryland
- Center for Cancer and Blood Disorders at Suburban Hospital - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316940
The ClinicalTrials.gov registry entry for NCT00316940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (95% lower). The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which bortezomib is the first listed.
NCT00316940 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT00316940 about?
NCT00316940 is a clinical study titled "Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to radiation. Giving sama...
What is the current status of trial NCT00316940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2005-12. Estimated completion is 2011-02.
What conditions does trial NCT00316940 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00316940?
The interventions under investigation include: bortezomib (DRUG), samarium Sm 153 lexidronam pentasodium (RADIATION).
Who is sponsoring clinical trial NCT00316940?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00316940 being conducted?
This trial has 4 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
COMPLETED · Phase 1
-
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
COMPLETED · Phase 1
-
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 1
-
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 1
-
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
COMPLETED · Phase 1
-
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.